| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LiquidSEQ™
Test Code14308
CPT Codes
<strong>This test is not available for New York and Wyoming patient testing.</strong>
Preferred Specimen
10 mL whole blood collected in each of two Streck cell-free DNA blood collection tubes
Minimum Volume
10 mL (x2)
Instructions
This test requires two Streck tubes. Blood will be collected in office via QUEST-LIQUIDSEQ GEN KIT. Specimens may be shipped separately and at different times. Do not hold blood specimen due to short stability. Do not reject. Blood collection using a straight needle is preferred. Use kit only. All tubes must be filled completely. Gently invert tube at least 8 times immediately after draw.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Do not reject, send to laboratory for testing assessment
Methodology
Next Generation Sequencing
Setup Schedule
Set up: Sun, Tue, Thu; Report available: 7-10 days
Clinical Significance
The 523-gene comprehensive genomic profiling panel is
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient's
blood. This comprehensive panel offers the opportunity for
a broader scope of genomic information compared to single
gene tests or smaller panels and an alternative specimen
type for comprehensive genomic profiling of a patient's
solid tumor. For example, it may be useful for patients
with limited or ill-defined treatment options and for those
considering clinical trials in the event tumor tissue is
not available or insufficient for tissue-based testing.
This panel uses next-generation sequencing to detect
mutations present in circulating tumor DNA (ctDNA)
extracted from a solid tumor patient's blood plasma. The
test is designed to detect single nucleotide variants
(SNVs) and small insertions/deletions, as well as
whole-gene copy number alterations and translocations in a
select group of genes. Microsatellite instability (MSI) and
tumor mutation burden (TMB) are also evaluated.
intended to help oncologists deliver precision medicine by
providing personalized genomic analysis of a patient's
blood. This comprehensive panel offers the opportunity for
a broader scope of genomic information compared to single
gene tests or smaller panels and an alternative specimen
type for comprehensive genomic profiling of a patient's
solid tumor. For example, it may be useful for patients
with limited or ill-defined treatment options and for those
considering clinical trials in the event tumor tissue is
not available or insufficient for tissue-based testing.
This panel uses next-generation sequencing to detect
mutations present in circulating tumor DNA (ctDNA)
extracted from a solid tumor patient's blood plasma. The
test is designed to detect single nucleotide variants
(SNVs) and small insertions/deletions, as well as
whole-gene copy number alterations and translocations in a
select group of genes. Microsatellite instability (MSI) and
tumor mutation burden (TMB) are also evaluated.
